Your browser is no longer supported. Please, upgrade your browser.
Settings
NTEC Intec Pharma Ltd. daily Stock Chart
NTEC [NASD]
Intec Pharma Ltd.
Index- P/E- EPS (ttm)-1.40 Insider Own11.40% Shs Outstand33.23M Perf Week24.37%
Market Cap244.21M Forward P/E- EPS next Y-1.00 Insider Trans0.00% Shs Float24.70M Perf Month26.94%
Income- PEG- EPS next Q- Inst Own40.62% Short Float2.35% Perf Quarter88.46%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio2.52 Perf Half Y61.54%
Book/sh1.97 P/B3.74 EPS next Y- ROA- Target Price12.70 Perf Year36.11%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.55 - 8.08 Perf YTD42.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-7.18% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low111.27% ATR0.40
Employees70 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)73.01 Volatility14.20% 5.62%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.41 Prev Close7.35
ShortableYes LT Debt/Eq- EarningsNov 21 AMC Payout- Avg Volume230.10K Price7.50
Recom1.60 SMA2020.11% SMA5030.91% SMA20047.68% Volume22,543 Change2.04%
Mar-26-18Reiterated Maxim Group Buy $8 → $12
Feb-28-18Initiated Ladenburg Thalmann Buy
Feb-26-18Initiated H.C. Wainwright Buy
Sep-21-17Reiterated Oppenheimer Outperform $10 → $15
Sep-16-15Initiated Maxim Group Buy $9
Sep-11-15Initiated ROTH Capital Buy $9.50
Dec-06-18 07:00AM  Intec Pharma to Continue Development Collaboration to Next Phase PR Newswire
Dec-03-18 06:50AM  Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma ACCESSWIRE +10.55%
Nov-21-18 08:55AM  Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-09-18 07:00AM  Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update PR Newswire
Nov-07-18 09:43AM  Israel's Intec Pharma eyes revenue from Parkinson's drug in 2019 Reuters
Nov-06-18 07:00AM  Intec Pharma to Participate in Upcoming November Investment Conferences PR Newswire
Nov-02-18 12:15PM  A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies Benzinga
Oct-22-18 07:00AM  Intec Pharma Completes Enrollment of Pivotal Phase 3 Clinical Trial of Accordion Pill Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients PR Newswire
Sep-25-18 07:00AM  Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society PR Newswire +11.11%
Sep-20-18 07:00AM  Intec Pharma to Participate at Upcoming Investment Conferences PR Newswire
Aug-15-18 07:30AM  Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update PR Newswire
Jul-20-18 06:00AM  5 Favorite Biotech Bets Investopedia
Jun-29-18 07:00AM  Intec Pharma Appoints William Bradley Hayes to Board of Directors PR Newswire
May-31-18 08:30AM  Intec Pharma to Present at Jefferies 2018 Healthcare Conference PR Newswire
May-15-18 07:00AM  Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update PR Newswire
Apr-26-18 07:40AM  Blog Exposure - Intec Pharma Shares Phase-1 PK and Safety Data from Accordion Pill Carbidopa/Levodopa at AAN Annual Meeting ACCESSWIRE
Apr-24-18 07:00AM  Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting PR Newswire
Apr-13-18 04:01PM  Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares PR Newswire
Apr-11-18 09:00AM  Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares PR Newswire -17.97%
Apr-10-18 04:01PM  Intec Pharma Announces Proposed Public Offering of Ordinary Shares PR Newswire
10:00AM  Intec Pharma (Nasdaq: NTEC) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire
Apr-04-18 08:00AM  Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting PR Newswire
Apr-03-18 08:00AM  Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease PR Newswire
Mar-26-18 07:00AM  Intec Pharma Appoints Roger J. Pomerantz, M.D. to Board of Directors PR Newswire
Mar-12-18 04:30PM  Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson's Disease PR Newswire
Mar-09-18 07:00AM  Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update PR Newswire +6.45%
Mar-05-18 07:15AM  Intec Pharma, Ltd. to Present at Four Investor Conferences in March PR Newswire
Jan-31-18 08:00AM  Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer PR Newswire
Jan-08-18 08:00AM  Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company PR Newswire
Jan-06-18 03:23PM  Pot Stock Winners of the Week Investopedia
Jan-03-18 08:00AM  Intec Pharma Granted Patent in Canada for Accordion Pill Carbidopa / Levodopa PR Newswire +7.44%
Nov-15-17 04:01PM  Intec Pharma Reports Third Quarter 2017 Operating and Financial Results PR Newswire
Nov-08-17 08:00AM  Intec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare Conference PR Newswire
Nov-01-17 07:00AM  Intec Pharma, Ltd. Announces Changes to its Board of Directors PR Newswire
07:00AM  Intec Pharma Ltd. Announces Changes to its Board of Directors PR Newswire
Oct-26-17 07:00AM  Intec Pharma Names Walt Linscott as Chief Administrative Officer PR Newswire
Oct-06-17 07:00AM  Intec Pharma to Participate in the Oppenheimer Specialty Pharma Summit PR Newswire
Sep-29-17 05:18PM  Pot Stock Winners of the Week Investopedia
Sep-20-17 07:00AM  Intec Pharma to Participate in the Ladenburg Thalmann 2017 Healthcare Conference PR Newswire
Sep-08-17 10:38AM  Intec Pharma to Participate in the 19th Annual Rodman & Renshaw Global Investment Conference PR Newswire
Sep-01-17 08:00AM  Intec Pharma to Participate in BioCentury's 24th Annual NewsMakers in the Biotech Industry Conference PR Newswire
Aug-22-17 08:15AM  Intec Pharma (NTEC) Catches Eye: Stock Adds 9.8% in Session Zacks
Aug-21-17 04:15PM  Intec Pharma Announces Closing of $57.5 Million Public Offering of Ordinary Shares PR Newswire +9.76%
Aug-16-17 09:00AM  Intec Pharma Announces Pricing of $50.0 Million Public Offering of Ordinary Shares PR Newswire +13.40%
Aug-15-17 04:01PM  Intec Pharma Announces Proposed Public Offering of Ordinary Shares PR Newswire
Aug-09-17 05:00PM  Intec Pharma Reports Financial Results for the First Six Months of 2017 PR Newswire
Aug-03-17 07:00AM  Intec Pharma Reports Clinical Results From Phase I Trial of Accordion Pill for Cannabinoid Therapies PR Newswire
Jul-27-17 08:00AM  Intec Pharma Promotes Nadav Navon, Ph.D. to Chief Operating Officer PR Newswire
Jul-19-17 08:00AM  Intec Pharma Granted Patent in Hong Kong for Accordion Pill Carbidopa / Levodopa PR Newswire
Jul-10-17 08:33AM  Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer PR Newswire
May-31-17 08:49AM  Intec Pharma to Participate at Upcoming June Conferences Business Wire
May-24-17 08:30AM  Intec Pharma Granted U.S. Patent for Accordion Pill Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms PR Newswire
May-03-17 04:00AM  Intec Pharma Announces CEO Change PR Newswire
Apr-09-17 02:15AM  Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman PR Newswire
Apr-07-17 08:00AM  Intec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results PR Newswire
Mar-29-17 07:30AM  Intec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients PR Newswire
Mar-22-17 07:00AM  Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies PR Newswire
Mar-17-17 04:00PM  Intec Pharma to Participate in the Oppenheimer 27th Annual Healthcare Conference PR Newswire
Mar-10-17 08:54AM  Intec Pharma to Participate in the 29th Annual Roth Conference Business Wire
08:00AM  Intec Pharma Announces $10 Million Private Placement PR Newswire
Nov-28-16 07:30AM  Intec Pharma Enters into Agreement with the Michael J. Fox Foundation Around Its Phase III Trial Recruitment PR Newswire
Nov-09-16 07:30AM  Intec Pharma to Sponsor Investigator Meeting for Pivotal Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients PR Newswire
Nov-07-16 06:00AM  Intec Pharma Announces Protocol Amendment to Phase III Study of Accordion Pill Carbidopa/Levodopa in Advanced Parkinson's Disease Patients PR Newswire
Oct-31-16 08:00AM  Intec Pharma Granted Chinese Patent for Accordion PillTM Carbidopa / Levodopa Business Wire
Sep-07-16 03:21PM  Intec Pharma to Participate in Upcoming September Conferences Business Wire
Sep-06-16 07:30AM  Intec Pharma Granted European Patent for Accordion PillCarbidopa / Levodopa Business Wire
Sep-01-16 06:00AM  Intec Pharma Reports First Half 2016 Financial Results Business Wire
Aug-04-16 06:00AM  Intec Pharma to Pursue Development of Accordion Pill for Cannabinoid Therapies Business Wire
Jun-03-16 08:00AM  Intec Pharma Announces Planned Management Changes PR Newswire
May-31-16 08:30AM  Intec Pharma Receives Approval for US$5.2 Million Grant PR Newswire
May-16-16 08:30AM  Intec Pharma to Nominate Dr. John W. Kozarich as Chairman of the Board of Directors PR Newswire
May-03-16 08:00AM  Intec Pharma Appoints VP of Clinical and Regulatory Affairs PR Newswire
Apr-06-16 07:00AM  Intec Pharma Expands Intellectual Property for AP-CDLD with Patent in South Korea PR Newswire
Apr-04-16 07:00AM  Intec Pharma Enrolls First Patient in Pivotal Phase III Clinical Trial of AP-CDLD for Advanced Parkinson's Disease Patients PR Newswire
Mar-17-16 01:04PM  INTEC PHARMA LTD. Financials
10:30AM  Mr. Zvika Joseph to Step Down as Chairman of the Board of Directors Marketwired
Mar-14-16 07:45AM  Intec Pharma Reports 2015 Fourth Quarter and Full-Year Financial Results Marketwired
07:30AM  Intec Pharma Ltd. Announces Availability of Its Annual Report on Form 20-F Through Its Website Marketwired
07:15AM  Intec Pharma Ltd.: Notice of Special General Meeting of Shareholders Marketwired
Mar-10-16 08:00AM  Intec Pharma Completed a Phase I Clinical Trial With Its Third Pipeline Product Marketwired
Jan-05-16 07:00AM  Intec Pharma to Present at Biotech Showcase 2016 Marketwired
Dec-16-15 07:00AM  Intec Pharma Further Expands Intellectual Property With a New Patent for the Accordion Pill Zaleplon in Europe Marketwired
Dec-14-15 08:09AM  Intec Pharma Receives an IRB Approval to Initiate Phase III Clinical Trial of AP - CDLD for the Treatment of Parkinson's Disease Marketwired
Dec-08-15 08:30AM  Intec Pharma Enters Phase I Clinical Trial With Its Third Pipeline Product Marketwired
Dec-01-15 05:51PM  Is Intec Pharma Ltd (NTEC) Going to Burn These Hedge Funds? at Insider Monkey
Nov-05-15 04:30PM  Intec Pharma Reports Results for the Third Quarter of 2015 Marketwired
Oct-22-15 08:30AM  Intec Pharma Expands Intellectual Property With a New Patent for the Accordion Pill in Europe Marketwired
Oct-12-15 09:37PM  Intec Pharma Announces Topline Results of a Food Effect, Pharmacokinetic Study of AP-CDLD 50/500mg for the Treatment of Parkinson's Disease Symptoms Marketwired
Sep-17-15 05:58PM  Intec Pharma Ltd. Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares Marketwired
12:01AM  Intec Pharma May Have a Blockbuster at Barrons.com
Aug-04-15 09:25AM  Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering PR Newswire
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.